iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
2 New 1st-In-Class HCV Drugs: microRNA miR-122& p7 Inhibitor BIT225 which also has HIV Activity
 
 
  AASLD: Anti-viral Proof of Concept Study of Miravirsen, an OligonucleotideTargeting miR-122, in Treatment Naïve Patients with Genotype 1 Chronic HCV Infection - (12/07/11)

AASLD: Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged antiviral activity of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients - press release - (12/07/11)

HepDART: Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months: 'First-in-class, new mode of action drug, Novel p7 inhibitor with the potential to increase the potency of current anti-HCV therapy' - 'BIT225 is a novel antiviral compound that inhibits the viroporin function of HIV-1 Vpu and HCV p7.....and a potentially useful agent to target cellular viral reservoirs' (12/08/11)

HepDART: Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-na•ve, genotype 1, mono-infected patients (12/08/11)

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org